| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $294.8M | +13.8% |
| SG&A Expense | $104.1M | +24.4% |
| Operating Income | -$398.9M | -16.4% |
| Net Income | -$395.9M | -15.7% |
| EPS (Basic) | -$2.49 | -11.7% |
| EPS (Diluted) | -$2.49 | -11.7% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $231.7M | +196.2% |
| Short-term Investments | $240.1M | -43.7% |
| Current Assets | $479.1M | -5.7% |
| Total Assets | $664.0M | -14.6% |
| Current Liabilities | $91.5M | +2.6% |
| Total Liabilities | $164.3M | +5.6% |
| Stockholders' Equity | $499.6M | -19.6% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$292.8M | -28.4% |
| Capital Expenditures | $20.4M | -45.6% |
| Investing Cash Flow | $256.5M | — |
| Financing Cash Flow | $190.2M | -20.5% |
| Free Cash Flow | -$313.2M | -18.0% |